ROIV
Roivant Sciences Ltd (ROIV)
NASDAQ · Healthcare
Roivant Sciences Ltd annual/quarterly shareholder equity history from 2021 to 2026. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Roivant Sciences Ltd shareholder equity for the quarter ending March 31, 2026 were 4.53B, a 3.42% decrease year-over-year.
- Roivant Sciences Ltd shareholder equity for 2026 were 4.53B, a 3.42% decrease from 2025.
- Roivant Sciences Ltd shareholder equity for 2025 were 4.69B, a 21.46% decrease from 2024.
- Roivant Sciences Ltd shareholder equity for 2024 were 5.97B, a 415.53% increase from 2023.
- Roivant Sciences Ltd shareholder equity for 2023 were 1.16B.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Roivant Sciences Ltd Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2026 | $4,527 |
| 2025 | $4,688 |
| 2024 | $5,969 |
| 2023 | $1,158 |
| 2022 | $1,657 |
| 2021 | $1,798 |
| Roivant Sciences Ltd Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2026-03-31 | $4,527 |
| 2025-03-31 | $4,688 |
| 2024-03-31 | $5,969 |
| 2023-03-31 | $1,158 |
| 2022-03-31 | $1,657 |
| 2021-03-31 | $1,798 |
Roivant Sciences Ltd Shareholder Equity — FAQ
Roivant Sciences Ltd (ROIV) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ROIV's shareholder equity history?
The chart and table above show Roivant Sciences Ltd's shareholder equity by year and by quarter, including the growth rate.